This page shows the latest Corlaner news and features for those working in and with pharma, biotech and healthcare.
Amgen is a recent entrant into the cardiovascular drugs arena, with recently-approved cholesterol-lowering drug Repatha (evolocumab) and heart failure drug Corlaner (ivabradine) spearheading its assault on the market.
Firm also reports healthy financial growth in the first quarter. . Amgen has started shipping its Corlaner heart failure therapy to wholesalers in the US just a few days after getting FDA ... Corlaner (ivabradine) - the first new medicine for chronic
The FDA approved Corlaner (ivabradine) after a priority review for reducing the risk of hospitalisation for worsening heart failure in patients with stable, symptomatic chronic heart failure (CHF). . ... Corlaner's approval is based on the results of
year. These are evolocumab for high cholesterol, heart failure drug Corlaner (ivabradine) and talimogene laherparepvec (T-VEC) for melanoma. ... Despite the upbeat comments, Amgen did reveal that Corlaner and T-VEC have both been delayed by requests for
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Corlaner costs around the same as Entresto at around $4, 500 per year. ... Entresto and Corlaner are expected to account for the bulk of that increase, with Entresto taking the lion's share.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...